Beijing, China – 15 Sep 2026 – The Center for Medical Device Evaluation (CMDE) of China’s National Medical Products Administration (NMPA) announced a public consultation on two draft registration review guidelines — the Guidelines for Clinical Evaluation and Registration Review of AI‑Assisted Multi‑Disease Decision‑Making Medical Devices (Draft for Comments) and the Guidelines for Clinical Evaluation and Registration Review of Implantable Deep Brain Stimulation (DBS) Systems (Draft for Comments) — with feedback due by 14 October 2026.
Consultation Snapshot
| Item | Detail |
|---|---|
| Agency | CMDE, under the National Medical Products Administration (NMPA), China |
| Action | Public solicitation of opinions on two draft technical review guidelines |
| Document 1 | AI‑assisted multi‑disease decision‑making medical devices – clinical evaluation & registration review |
| Document 2 | Implantable deep brain stimulation (DBS) systems – clinical evaluation & registration review |
| Notice Date | 15 September 2026 |
| Comment Deadline | 14 October 2026, via email using the prescribed feedback form and subject‑line naming convention |
| Original Notice | cmde.org.cn (published 16 September 2026) |
Guideline Scope & Submission Channels
- Document 1 – AI Multi‑Disease Decision Devices: Targets software‑based devices that assist clinical decision‑making across multiple diseases, defining clinical evaluation and registration review requirements. Detailed technical provisions were not disclosed in the notice itself; the full draft is available for download from CMDE.
- Document 2 – Implantable DBS Systems: Sets out clinical evaluation and registration review requirements for implantable deep brain stimulation systems, a class of active implantable neurostimulation devices.
- Submission Format: Comments must be filed via the official feedback form (Annex 3) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
- Contacts – AI Guideline: Wang Zehua, Jiang Yan, Dong Zheng (wangzh@cmde.org.cn, jiangyan@cmde.org.cn, dongzheng@cmde.org.cn).
- Contacts – DBS Guideline: Cui Xinyue, Guo Jiaying, Jin Yaxi (cuixy@cmde.org.cn, guojy@ydcmdei.org.cn, jinyx@cmde.org.cn) — with a Shanghai contact number indicating involvement of CMDE’s Yangtze River Delta branch.
Sector Background
- AI as a Medical Device (SaMD): China has progressively built a review framework for AI‑enabled diagnostic software. Extending dedicated guidance to multi‑disease decision support reflects the regulator’s response to algorithms that synthesize patient data across indications rather than addressing a single disease — a materially more complex clinical evaluation problem.
- Deep Brain Stimulation: DBS is an established implantable therapy for movement disorders such as Parkinson’s disease, with China’s market served by both global manufacturers (Medtronic, Abbott, Boston Scientific) and domestic players (PINS Medical, SceneRay).
- Guideline System: CMDE technical review guidelines standardize registration dossiers and evaluation criteria; public consultation is the customary step before guidelines are finalized and take effect.
Market Impact & Outlook
- Regulatory Clarity: Codified evaluation criteria for AI decision‑support software and implantable neurostimulators reduce approval uncertainty for developers and shorten pre‑submission negotiations.
- AI‑MedTech Landscape: Sponsors of multi‑disease AI platforms — including hospital‑affiliated developers and health‑AI startups — should benchmark their clinical evidence strategies against the draft before the final guideline lands.
- Neuromodulation Standardization: A dedicated DBS guideline aligns China’s review expectations with the maturity of its neurostimulation market, benefiting both multinationals and domestic manufacturers pursuing registration or next‑generation product iterations.
- Participation Window: Industry stakeholders have until 14 October 2026 to shape the final requirements — an opportunity to flag practical concerns on clinical evaluation design, real‑world evidence, and post‑market obligations.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of draft guidelines, and their potential impact on medical device registration in China. The drafts are subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916105408164.html